Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

详细信息    查看全文

• 作者：Yuka Matsuda ; Kenji Okita ; Tomohisa Furuhata ; Goro Kutomi…
• 关键词：Chemotherapy ; induced nausea and vomiting ; MASCC antiemesis tool ; Antiemetics ; Symptom evaluation
• 刊名：Supportive Care in Cancer
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：23
• 期：11
• 页码：3331-3339
• 全文大小：590 KB
• 参考文献：1.Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end鈥損atient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203鈥?08CrossRef PubMed
  2.Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1993) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189鈥?95CrossRef
  3.de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055鈥?061PubMed Central CrossRef PubMed
  4.Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7:59鈥?5CrossRef PubMed
  5.Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155鈥?63CrossRef PubMed
  6.Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Rd W, Carides AD, Taylor A, Evans JK, Horqan KJ (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278鈥?285CrossRef PubMed
  7.Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19:823鈥?32CrossRef PubMed
  8.Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla R (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340鈥?346PubMed Central CrossRef PubMed
  9.National Comprehensive Cancer Network: Antiemesis Guidelines version 1 (2014) http://鈥媤ww.鈥媙ccn.鈥媜rg/鈥媝rofessionals/鈥媝hysician_鈥媑ls/鈥媝df/鈥媋ntiemesis.鈥媝df
  10.Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189鈥?198CrossRef PubMed
  11.Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232鈥?43CrossRef
  12.Aapro M, Molassiotis A, Dicato M, Pel谩ez I, Rodr铆guez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986鈥?992CrossRef PubMed
  13.Fern谩ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Su谩rez C, Zorrilla I, G贸mez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients鈥?quality of life. Support Care Cancer 20:3141鈥?148CrossRef PubMed
  14.Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2012) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219鈥?27CrossRef
  15.Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115鈥?24CrossRef PubMed
  16.Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol鈥擡ASE. J Clin Oncol 29:1495鈥?501CrossRef PubMed
  17.Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261鈥?268CrossRef PubMed
  18.Majem M, Moreno ME, Calvo N, Feliu A, P茅rez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983鈥?990CrossRef PubMed
  19.Multinational Association of Supportive Care in Cancer: MASCC antiemesis tool Japanese. http://鈥媤ww.鈥媘ascc.鈥媜rg/鈥媋ssets/鈥媎ocuments/鈥婱AT_鈥媕apanese_鈥媞uestionaire_鈥?010.鈥媎oc
  20.Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34:148鈥?59CrossRef
  21.Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the index of nausea and vomiting. Oncol Nurs Forum 26:889鈥?94PubMed
  22.National Cancer Institute: Patient-reported outcomes version of the CTCAE (PRO-CTCAE). https://鈥媤iki.鈥媙ci.鈥媙ih.鈥媑ov/鈥媎isplay/鈥婸ROCTCAE/鈥婸atient-Reported_鈥婳utcomes_鈥媣ersion_鈥媜f_鈥媡he_鈥婥TCAE_鈥?/span>
  23.Japan Society of Clinical Oncology (2010) JSCO guidelines for antiemetics in oncology 2010. Kanehara & Co., Ltd., Tokyo
  24.Morrow GR (1984) Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer 53:2267鈥?278CrossRef PubMed
  25.Osoba D, Zee B, Pater J, Warr D, Latrielle J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116鈥?23PubMed
  26.Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98:645鈥?55CrossRef PubMed
  27.Lindley CM, Hirsch JD, O鈥橬eill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331鈥?40CrossRef PubMed
  28.Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM (2003) Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395鈥?401CrossRef PubMed
  29.Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179鈥?85CrossRef PubMed
  30.Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients鈥?quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472鈥?478CrossRef PubMed
  
• 作者单位：Yuka Matsuda (1)
  Kenji Okita (2)
  Tomohisa Furuhata (2)
  Goro Kutomi (2)
  Kentaro Yamashita (3)
  Yasushi Sato (4)
  Rishu Takimoto (4)
  Koichi Hirata (2)
  
  1. Department of Nursing, Outpatient Chemotherapy Center, Sapporo Medical University, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
  2. Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan
  3. Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan
  4. Department of Medical Oncology and Hematology, Sapporo Medical University, Sapporo, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose The Multinational Association of Supportive Care in Cancer (MASCC) developed the MASCC antiemesis tool (MAT) as a tool for chemotherapy-induced nausea and vomiting (CINV) assessment and subsequently published its Japanese version in 2010. We evaluated the validity of CINV assessment in outpatients using the Japanese version of MAT.